Another setting in which compensatory mechanisms within BAF‐complexes lead to synthetic lethality that can be leveraged for targeted cancer therapies is cancers with SMARCB1 mutations, found in a variety of mesenchymal neoplasms including rhabdoid tumors and other sarcomas.244. This evidence concerns the gene SMARCB1 and cancer.